Therapy of invasive bladder cancer

Urology

Volumn 67, Issue 3 SUPPL. 1, 2006, Pages 56-59

  Dinney, Colin P N ^a,b,c,d   Grossman, H Barton ^c   Liou, Louis S ^c   Blute, Michael L ^c   Reuter, Victor E ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Abbott Molecular/Abbott Laboratories Inc ^*

^d Abbott Molecular Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEMCITABINE; METHOTREXATE; TAXANE DERIVATIVE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER STAGING; CYSTECTOMY; HUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 33644764893     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.01.043     Document Type: Article

References (21)

1. B. Czerniak F. Herz Molecular biology of common genito-urinary tumors in cytology of genito-urinary tumors L.D. Koss Diagnostic Cytology of the Urinary Tract 1995 Lippincott-Raven Philadelphia 345 364
2. C. Cordon-Cardo J. Sheinfeld G. Dalbagni Genetic studies and molecular markers of bladder cancer Semin Surg Oncol 13 1997 319 327
3. I.D. Markl P.A. Jones Presence and location of TP53 mutations determines patterns of CDKN2A/ARF pathway in bladder cancer Cancer Res 58 1998 5348 5353
4. R.J. Cote M.D. Dunn S.J. Chatterjee Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53 Cancer Res 58 1998 1090 1094
5. D. Esrig D. Elmajian S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259 1264
6. R.J. Cote D. Esrig S. Groshen p53 and treatment of bladder cancer Nature 385 1997 123 125
7. A.S. Sarkis D.F. Bajorin V.E. Reuter Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC J Clin Oncol 13 1995 1384 1390
8. L. Cheng A.L. Weaver B.C. Leibovich Predicting the survival of bladder carcinoma patients treated with radical cystectomy Cancer 88 2000 2326 2332
9. H.W. Herr B.H. Bochner G. Dalbagni Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer J Urol 167 2002 1295 1298
10. R.F. Sanchez-Ortiz W.C. Huang R. Mick An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma J Urol 169 2003 110 115
11. L.S. Elting C. Pettaway B.N. Bekele Correlation between annual volume of cystectomy, professional staffing, and outcomes Cancer 104 2005 975 984
12. M.D. Michaelson W.U. Shipley N.M. Heney Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder Br J Cancer 90 2004 578 581
13. R. Millikan C. Dinney D. Swanson Integrated therapy for locally advanced bladder cancer final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC J Clin Oncol 19 2001 4005 4013
14. H.B. Grossman R.B. Natale C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
15. H.W. Herr J.R. Faulkner H.B. Grossman Surgical factors influence bladder cancer outcomes a cooperative group report J Clin Oncol 22 2004 2781 2789
16. W.M. Stadler S.P. Lerner Commentary perioperative chemotherapy in locally advanced bladder cancer Lancet 361 2003 1922 1923
17. S.M. Donat H.W. Herr D.F. Bajorin Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer J Urol 156 1996 368 371
18. A.O. Siefker-Radtke G.L. Walsh L.L. Pisters Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience J Urol 171 2004 145 148
19. P. Sweeney R. Millikan M. Donat Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 169 2003 2113 2117
20. C.N. Sternberg A. Yagoda H.I. Scher Preliminary results of methotrexate, vinblastine, Adriamycin and cisplatin (M-VAC) in advanced urothelial tumors J Urol 133 1985 403 407
21. H. von der Maase S.W. Hansen J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer results of a large, randomized multinational multicenter phase III study J Clin Oncol 18 2000 3068 3077